Want to join the conversation?
$ABBV 2Q15 Call: Earlier this year, we entered into collaboration with C2N Diagnostics to develop and commercialize a portfolio of anti-tau antibodies. We recently received an Orphan Drug Designation for HUMIRA and initiated a phase I program. We are on track to start clinical development with C2N in Alzheimer’s disease in 2016.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?